Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more
12/22/2023
/ Borrowers ,
Capital Markets ,
EBITDA ,
Environmental Social & Governance (ESG) ,
EU ,
Financing ,
Healthcare ,
Investment ,
Lenders ,
Life Sciences ,
Secondary Credit Markets ,
Technology Sector ,
Venture Capital
Past: Once Upon a Time -
Thinking back to pre-pandemic times, it cannot be said that the Italian private equity (PE) and venture capital (VC) market was particularly flourishing or on the rise. Funding was decreasing...more